PYRAZOLO QUINAZOLINE DERIVATIVE COMPOUNDS INDUCING SELECTIVE DEGRADATION OF PLK1

The present invention provides novel compounds that induce selective polo-like kinase 1 (PLK1) degradation. Specifically, the present invention provides a bifunctional compound in which a PLK1 binding moiety and an E3 ubiquitin ligase-binding moiety are linked by a chemical linker. The present inven...

Full description

Saved in:
Bibliographic Details
Main Authors NAM, Boas, CHOI, Si Woo, RYU, Hye Guk, RYU, Ji Hoon, RYU, Soo Hee, MIN, Im Suk, LEE, Hwa Jin, KIM, Seong Hoon, KANG, Keum Young, SON, San Ha
Format Patent
LanguageEnglish
French
Published 30.09.2021
Subjects
CHEMISTRY
HETEROCYCLIC COMPOUNDS
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
METALLURGY
ORGANIC CHEMISTRY
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
Online AccessGet full text

Cover

More Information
Summary:The present invention provides novel compounds that induce selective polo-like kinase 1 (PLK1) degradation. Specifically, the present invention provides a bifunctional compound in which a PLK1 binding moiety and an E3 ubiquitin ligase-binding moiety are linked by a chemical linker. The present invention provides the compound, a method for preparing the same, and the use thereof. The compounds may be effectively utilized for preventing or treating PLK1 related diseases. La présente invention concerne de nouveaux composés qui induisent la dégradation sélective de la kinase 1 de type polo (PLK1). Spécifiquement, la présente invention concerne un composé bifonctionnel dans lequel une fraction de liaison de PLK1 et une fraction de liaison de ligase d'ubiquitine E3 sont liées par un lieur chimique. La présente invention concerne le composé, son procédé de préparation et son utilisation. Les composés peuvent être utilisés efficacement pour prévenir ou traiter des maladies associées à PLK1.
Bibliography:Application Number: WO2021KR03809